Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026
PR Newswire•01/10/2026•08:00 ET
0
Key Highlights
- ➤MUC16 expression remained high and stable after standard-of-care therapies
- ➤High MUC16 expression associated with poor real-world overall survival in HGSOC
- ➤HWK-016 is a MUC16-directed ADC in ongoing Phase 1 development
- ➤MUC16 showed less treatment-associated variation than FRα, TROP2 and NaPi2b
Expert Statements
Margaret Dugan, Chief Medical Officer of Whitehawk Therapeutics
“For an ADC target to have broad clinical utility in ovarian cancer, it's important that it remains consistently expressed as patients move through multiple lines of therapy.”
Margaret Dugan, Chief Medical Officer of Whitehawk Therapeutics
“These findings suggest MUC16 is durable throughout the treatment continuum and support the exploration of HWK-016 both in combination with established therapies and in patients whose disease has progressed following prior treatment.”
Robert L. Coleman, Texas Oncology
“Ovarian cancer continues to be a difficult-to-treat disease with new therapeutic approaches urgently needed.”
Robert L. Coleman, Texas Oncology
“The observation that high MUC16 expression was independently associated with poorer real-world overall survival indicates it is an important marker of more aggressive disease biology, and supports the continued investigation of MUC16-directed ADCs in this disease.”
Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026 PR Newswire
MUC16 Expression Remained High and Stable Following Standard-of-Care Therapies, Supporting Its Potential Utility in Both Combination Approaches and Relapsed Settings
Get started
Create a free account to read the full story.